Highlights
- Prolonged medical therapy with antithyroid drugs (ATDs) has become the predominant management strategy in pediatric hyperthyroidism over the past two decades.
- There is a marked decrease in the use of definitive treatments (thyroidectomy, radioiodine ablation) correlating with an increased relapse and nonremission rate.
- Demographic and biochemical factors such as younger age, antithyroid peroxidase antibody positivity, and higher baseline free thyroxine levels are associated with longer time to remission.
- Emerging therapeutic adjuncts and precision medicine approaches warrant further study to optimize long-term outcomes in pediatric patients.
Background
Pediatric hyperthyroidism, predominantly caused by Graves’ disease (GD), presents unique diagnostic and therapeutic challenges due to differences in disease biology, psychosocial impact, and treatment tolerability compared to adults. Over the last two decades, there has been evolving practice regarding the balance between antithyroid drug therapy, definitive treatments (surgical thyroidectomy or radioactive iodine ablation), and observation. A major unmet need persists in optimizing protocols that maximize remission rates while minimizing adverse effects and long-term sequelae. Comprehensive understanding of temporal trends and factors influencing outcomes is critical to guide individualized care.
Key Content
Chronological Trends in Pediatric Hyperthyroidism Management
The retrospective cohort study by Oron et al. (2026) represents one of the largest and most methodologically robust analyses, encompassing 518 children diagnosed with hyperthyroidism from 2000 to 2019 with a median follow-up exceeding 10 years. The investigation revealed a clear shift from earlier eras (2000–2009) characterized by higher initial methimazole doses (mean 15.8 mg/day) and frequent definitive interventions (59.6%), toward the 2010–2019 decade with lower initial dosing (12.9 mg/day, p=0.030) and markedly reduced definitive treatments (27.5%, p<0.001).
This trend reflects a clinical paradigm favoring prolonged ATD therapy, interpreted as an attempt to avoid surgical or radiotherapeutic morbidity. However, this conservative treatment approach coincided with a significant increase in nonremission (19.0% vs. 3.8%, p<0.001) and relapse rates (15.9% vs. 4.6%, p<0.001) among the more recent cohort, suggesting potential trade-offs in disease course and control.
Clinical Outcomes and Predictors of Remission
Of the cohort achieving remission (31.1%), the median time to remission was 2.36 years. Notably, younger age and positivity for antithyroid peroxidase antibodies were predictive of delayed remission. Stratification by baseline thyroid hormone levels revealed that higher free thyroxine (FT4) at diagnosis portended later remission (42.4 vs. 32.6 pmol/L, p=0.014). These findings align with other pediatric studies, including an Argentine pediatric GD cohort (PMID 39736100), which also reported low remission rates (13%) and a substantial reliance on definitive treatment due to poor adherence and severe thyrotoxicosis.
Adjunctive and Alternative Therapies
While ATDs remain first-line therapy, there is growing interest in adjunctive agents and approaches. For adult GD and thyroid eye disease, monoclonal antibodies such as teprotumumab have demonstrated significant efficacy in modifying orbital disease (PMID 39714282) but remain largely investigational in pediatrics. Traditional Chinese medicine formulations (e.g., Pingkang granules combined with methimazole) have shown promise in reducing thyroid hormone levels and TRAb titers in adults (PMID 39550016), though pediatric data are limited.
Orbital decompression and glucocorticoid therapies continue to be mainstays in managing thyroid eye disease, a common extrathyroidal manifestation, with studies highlighting the timing and safety of interventions (PMIDs 39527723, 39656059). Moreover, immunomodulators such as rituximab have been evaluated as second-line options in steroid-resistant cases, albeit with mixed efficacy and limited pediatric-specific evidence (PMID 39672539).
Safety and Long-Term Prognosis
Adverse events related to ATDs, including agranulocytosis and hepatic dysfunction, are documented concerns but were not highlighted as predominant in the provided pediatric studies. Nevertheless, the increase in relapse and nonremission with prolonged medical management necessitates vigilance regarding cumulative disease burden and quality of life.
Expert Commentary
The data synthesized herein underline a significant shift toward conservative, prolonged ATD treatment in pediatric hyperthyroidism. This reflects an evolving understanding of the risk-benefit balance, attempting to mitigate the consequences of definitive therapies such as lifelong hypothyroidism and surgical complications. However, increased relapse rates after less aggressive interventions highlight the need for robust biomarkers and clinical predictors to guide personalized decision-making.
Current clinical guidelines recommend initial ATD therapy with thoughtful evaluation for definitive treatment in refractory or relapsing cases. The predictors identified—higher FT4 levels, younger age, and autoantibody profiles—could serve as valuable tools for timing interventions. Additionally, adherence issues emerge as a critical modifiable factor impacting outcomes, underscoring the importance of patient and family education in prolonged ATD regimens.
Integration of novel biologic agents and complementary therapies should be pursued cautiously, prioritizing high-quality pediatric trials to ensure safety and efficacy. The management of extrathyroidal manifestations, particularly thyroid eye disease, requires multidisciplinary care with tailored use of immunosuppressive and surgical interventions.
Conclusion
Over two decades, pediatric hyperthyroidism management has transitioned to extended medical therapy with reduced definitive treatments, reflecting an emphasis on safety and quality of life. However, this shift correlates with increased relapse and nonremission rates, presenting a clinical challenge.
Future research should focus on refining predictive models for remission, enhancing adherence strategies, and exploring emerging therapies within rigorous pediatric frameworks. Longitudinal studies are needed to ascertain the impact of these management trends on long-term pediatric outcomes, ultimately aiming to optimize therapy personalization in this vulnerable population.
References
- Oron T, Yackobovitch-Gavan M, Lazar L, Fisch-Shvalb N. Trends in Management and Outcomes of Pediatric Hyperthyroidism Over Two Decades. Thyroid. 2026 Jun 25;10507256261462523. PMID: 42347684.
- González M et al. Pediatric Graves’ disease in Argentina: analyzing treatment strategies and outcomes. J Pediatr Endocrinol Metab. 2024;38(2):155-161. PMID: 39736100.
- Xu L et al. Clinical and Radiologic Predictors of Response to Teprotumumab: A 3D Volumetric Analysis of 35 Patients. Ophthalmic Plast Reconstr Surg. 2025 Jul-Aug;41(4):408-414. PMID: 39714282.
- Zhang R et al. Clinical efficacy of Chinese herbal medicine formula for Graves’ hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial. J Ethnopharmacol. 2025 Feb 10;338(Pt 3):119106. PMID: 39550016.
- Fischer-Szwalb N et al. Intraocular Pressure Changes After Combined Orbital Decompression and Glucocorticoid Treatment for Graves Orbitopathy. J Craniofac Surg. 2025 Jun;36(4):e371-e374. PMID: 39527723.
- Ornstein T et al. Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves’ Orbitopathy: A Nonrandomized, Controlled, Interventional Study. Endocr Pract. 2025 Apr;31(4):447-454. PMID: 39672539.